This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           March 25, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Angelina Jolie Pitt: Diary of a Surgery
The New York Times
Angelina Jolie Pitt writes: Two years ago I wrote about my choice to have a preventive double mastectomy. A simple blood test had revealed that I carried a mutation in the BRCA1 gene. It gave me an estimated 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer. I lost my mother, grandmother and aunt to cancer. I wanted other women at risk to know about the options. I promised to follow up with any information that could be useful, including about my next preventive surgery, the removal of my ovaries and fallopian tubes.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Special Interest Session VIII: DoD Ovarian Academy Abstract Session
Find out about the latest science coming from the Department of Defense’s Ovarian Academy during Special Interest Session VIII: Department of Defense Ovarian Academy Abstract Session on Monday, March 30, from 4:00 p.m. – 5:15 p.m. at the Hilton Chicago during the SGO Annual Meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


ENDOMETRIAL CANCER


Endometrial Cancer ACOG SGO Practice Bulletin
ACOG and SGO
Endometrial carcinoma is the most commonly diagnosed gynecologic malignancy; almost every gynecologist will encounter it. A thorough understanding of the epidemiology, pathophysiology, and diagnostic and management strategies for this type of cancer allows the obstetrician–gynecologist to identify women at increased risk, contribute toward risk reduction, and facilitate early diagnosis. The purpose of this document is to review the current understanding of endometrial cancer and to provide guidelines for management that have been validated by appropriately conducted outcome-based research when available.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


OVARIAN CANCER


Intraperitoneal chemotherapy improves 10-year ovarian cancer survival
Cancer Network
The use of intraperitoneal (IP) chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit that extended beyond 10 years compared with intravenous chemotherapy, according to a pooled analysis of data from the Gynecologic Oncology Group (GOG) protocols 114 and 172. “The long-term survival benefits described in this report may encourage more clinicians to adopt IP chemotherapy in the community,” Devansu Tewari, MD and colleagues wrote in the Journal of Clinical Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Early-onset alopecia may signal chemotherapy response for ovarian cancer
Cancer Network
Onset of alopecia, a common side effect of chemotherapy, within the first 3 cycles of platinum- and taxane-based chemotherapy was associated with improved overall survival (OS) among patients with epithelial ovarian cancer who completed 6 cycles of treatment. These results, published in the European Journal of Cancer, are taken from a meta-analysis of four prospective phase III trials that included 5,114 patients assigned platinum- and taxane-based chemotherapy for advanced epithelial ovarian cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.
MORE


SURVIVORSHIP


Complementary therapies can boost survival in cancer patients
Medscape (Free login required)
A large percent of cancer patients use some form of complementary and alternative medicine (CAM), typically with the goal of relieving pain and controlling the adverse effects of disease or treatment. A new review of evidence drawn from experimental and epidemiologic studies, as well as a few clinical trials, demonstrates that several of the integrative approaches and lifestyle changes might also influence cancer survivorship. The review was published online in Current Oncology Reports.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


RESEARCH


Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis
Oncogene
The cross-talk between ovarian cancer (OvCa) cells and the metastatic microenvironment is an essential determinant of successful colonization. MicroRNAs (miRNAs) have several critical roles during metastasis; however, the role of microenvironmental cues in the regulation of miRNAs in metastasizing cancer cells has not been studied.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


BREAST CANCER


Pathologists interpreting breast biopsy highly accurate
Cancer Therapy Advisor
Individual pathologists' interpretations of a single breast biopsy slide generally concur with expert consensus-derived reference diagnoses, according to a study published in the Journal of the American Medical Association. Joann G. Elmore, MD, MPH, from the University of Washington in Seattle, and colleagues quantified the magnitude of diagnostic disagreement among pathologists compared with a consensus panel reference diagnosis in interpretation of breast biopsies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


DOCUMENTARY


PBS to air in 'Cancer: The Emperor of all Maladies'
New York Daily News
If we can't always beat cancer, says Ken Burns, at least we need to strip away some of its psychological power. “No other disease has the same impact as cancer,” says Burns, executive producer of “Cancer: The Emperor of All Maladies,” a three-part PBS series that will air March 30-April 1. It's directed by Barak Goodman and based on a book by Dr. Siddhartha Mukherjee.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

March 18, 2015
March 11, 2015
March 4, 2015
Feb. 25, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063